The in vitro performance of Wixela Inhub is comparable to that of Advair Diskus at all dosage strengths (100/50μg, 250/50μg, and 500/50μg) and all flow rates. Wixela Inhub has pharmacokinetic and pulmonary therapeutic bioequivalence to Advair Diskus, which has well-established efficacy,...